Patient & Visitor InformationContact Us
  • Trials

  • Current Clinical Trials

    The OSCCC serves as the academic clinical coordinating center for a multicenter, Phase III investigational agents in patients with severe sepsis. The current trial represents the sixth multicenter trial that the OSCCC has coordinated since its inception in April 2004. 

    Past Trials

    The OSCCC served as the academic clinical coordinating center for the Agennix Incorporated's nationwide, multi-center, phase III trial of the investigational drug Talactoferrin (TLF). TLF was studied in patients with severe sepsis.

    The OSCCC served as the academic clinical coordinating center for the AstraZeneca global, multi-center, phase IIb trial of the investigational drug CytoFab (AZD9773). AZD9773 was studied in patients with severe sepsis.

    The OSCCC served as the academic clinical coordinating center for the Agennix Incorporated's nationwide, multi-center, phase II trial of the investigational drug Talactoferrin (TLF). TLF was studied in patients with severe sepsis.

    The OSCCC served as a clinical coordinating center for Eisai Pharmaceutical’s ACCESS trial. This was a global multi-center, Phase III trial of the investigational drug Eritoran Tetrasodium. OSCCC oversaw enrollment authorization for patients in North America, South America and Asia Pacific regions.

    The OSCCC served as one of the two clinical coordinating centers for the Novartis Pharmaceuticals' global multi-center, Phase III trial of the investigational drug Tifacogin. OSCCC handled enrollment authorization for patients with severe community acquired pneumonia (sCAP) in North America, South America, and Asia Pacific regions.